Literature DB >> 26497527

Accelerating antibody discovery using transgenic animals overexpressing the neonatal Fc receptor as a result of augmented humoral immunity.

Judit Cervenak1, Roland Kurrle2, Imre Kacskovics1,3.   

Abstract

In recent years, there has been an increasing demand for the development of faster and more efficient technologies for the generation of monoclonal antibodies against challenging targets that are weakly immunogenic or available only in limited amounts. Typical classes of such targets are cell surface antigens such as G-protein related receptors (GPCRs) or ion channels. We have developed transgenic (Tg) mice and rabbits that overexpress the neonatal Fc receptor (FcRn), resulting in an augmented humoral immune response even if challenging antigens are used for immunization. The impressively enhanced FcRn-mediated immune reactions are characterized by improved IgG protection and enhanced antigen presentation leading to greater number of antigen-specific T-helper and B-cell activation in lymphoid organs. Notably, these animals do not show any sign of autoimmunity and can be efficiently bred. FcRn overexpression thus leads to a number of practical benefits for improved generation of monoclonal and polyclonal antibodies against multiple antigens, including weakly immunogenic epitopes or tiny amounts of proteins. This review summarizes our current understanding about the mechanisms by which FcRn overexpression leads to such a significantly enhanced humoral immune response.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  B-cell activation; antigen presentation; monoclonal and polyclonal antibody generation; neonatal Fc receptor

Mesh:

Substances:

Year:  2015        PMID: 26497527     DOI: 10.1111/imr.12364

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  8 in total

1.  Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.

Authors:  Sai Kiran Sharma; Andrew Chow; Sebastien Monette; Delphine Vivier; Jacob Pourat; Kimberly J Edwards; Thomas R Dilling; Dalya Abdel-Atti; Brian M Zeglis; John T Poirier; Jason S Lewis
Journal:  Cancer Res       Date:  2018-01-23       Impact factor: 12.701

2.  Characterization of the interactions of rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG isotypes.

Authors:  Bence Szikora; László Hiripi; Balázs Bender; Imre Kacskovics; Attila Iliás
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

3.  ORAI2 modulates store-operated calcium entry and T cell-mediated immunity.

Authors:  Martin Vaeth; Jun Yang; Megumi Yamashita; Isabelle Zee; Miriam Eckstein; Camille Knosp; Ulrike Kaufmann; Peter Karoly Jani; Rodrigo S Lacruz; Veit Flockerzi; Imre Kacskovics; Murali Prakriya; Stefan Feske
Journal:  Nat Commun       Date:  2017-03-15       Impact factor: 14.919

4.  Strategies for Generating Diverse Antibody Repertoires Using Transgenic Animals Expressing Human Antibodies.

Authors:  Weihsu C Chen; Christopher M Murawsky
Journal:  Front Immunol       Date:  2018-03-07       Impact factor: 7.561

5.  FcRn Overexpression Expands Diversity of the Humoral Immune Response in bFcRn Transgenic Mice.

Authors:  Bence Szikora; Anita Marx; Péter K Jani; Orsolya Pipek; Viktor Müller; István Csabai; Imre Kacskovics
Journal:  Front Immunol       Date:  2020-08-21       Impact factor: 7.561

Review 6.  Innovative Immunization Strategies for Antivenom Development.

Authors:  Erick Bermúdez-Méndez; Albert Fuglsang-Madsen; Sofie Føns; Bruno Lomonte; José María Gutiérrez; Andreas Hougaard Laustsen
Journal:  Toxins (Basel)       Date:  2018-11-02       Impact factor: 4.546

Review 7.  Immunoglobulin Transporting Receptors Are Potential Targets for the Immunity Enhancement and Generation of Mammary Gland Bioreactor.

Authors:  Xuemei Jiang; Jianjun Hu; Diraviyam Thirumalai; Xiaoying Zhang
Journal:  Front Immunol       Date:  2016-06-10       Impact factor: 7.561

Review 8.  Dendritic cell biology and its role in tumor immunotherapy.

Authors:  Yingying Wang; Ying Xiang; Victoria W Xin; Xian-Wang Wang; Xiao-Chun Peng; Xiao-Qin Liu; Dong Wang; Na Li; Jun-Ting Cheng; Yan-Ning Lyv; Shu-Zhong Cui; Zhaowu Ma; Qing Zhang; Hong-Wu Xin
Journal:  J Hematol Oncol       Date:  2020-08-03       Impact factor: 17.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.